Genentech
↗South San Francisco, California, United States
Genentech is a pioneering biotechnology company founded in 1976 and widely recognized as the founder of the modern biotechnology industry. The company specializes in discovering, developing, and commercializing medicines for serious and life-threatening diseases, with a particular focus on oncology, immunology, and rare diseases. Since its founding, Genentech has become a leader in biopharmaceutical innovation, leveraging advanced technologies including monoclonal antibodies, antibody-drug conjugates, immunotherapy, and gene therapy. Operating as a wholly owned subsidiary of Roche Group (acquired in 2009), Genentech maintains significant operational independence and continues to drive innovation across its diverse therapeutic portfolio. The company has delivered transformative medicines to patients globally and maintains a robust pipeline of over 100 investigational compounds.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Biopharmaceuticals - Oncology, Immunology, Rare Disease
SIZE & FINANCIALS
Employees:10000+
Revenue:$5B-$10B+ (as subsidiary of Roche)
Founded:1976
Ownership:subsidiary
Status:operating
FUNDING
Investors:Kleiner Perkins Caufield & Byers (original venture capital funding, 1976)
PIPELINE
Stage:Discovery through Commercial
Lead Drug Stage:Marketed (multiple blockbusters)
Modalities:Monoclonal Antibodies (mAb), Antibody-Drug Conjugates (ADC), Bispecific Antibodies, Checkpoint Inhibitors, Small Molecules, Gene Therapy, Cell Therapy, RNA-based Therapeutics, Recombinant Proteins
Trial Phases:-
FDA Approvals:18
CORPORATE STRUCTURE
Parent Company:Roche Holding AG
Acquired By:Roche Holding AG (2009-03-01)
Key Partnerships:Caris Life Sciences - AI-driven oncology target discovery ($1.1B potential milestone deal, 2025), COUR Pharmaceuticals - Tolerogenic nanoparticles for autoimmune disease (up to $900M+ milestones, 2024), GenEdit - Nanoparticle delivery for nucleic acid medicines (autoimmune, 2024), Repertoire Immune Medicines - T cell-targeted immune therapies ($730M+ potential milestones, 2025), Starpharma - DEP drug delivery technology for cancer ($564M+ potential milestones, 2025), OMass Therapeutics - Oral small molecules for inflammatory bowel disease (2025), Roche Group - Parent company and strategic collaborator
COMPETITION
Position:Leader
Competitors:Amgen, Gilead Sciences, Biogen, Novartis, Bayer, Merck, AbbVie, Bristol-Myers Squibb +10 more
LEADERSHIP
Key Executives:
Ashley Magargee - Chief Executive Officer
Levi Garraway - Chief Medical Officer, Executive Vice President, Head of Global Product Development
Matteo Pietra - Chief Financial Officer
Aviv Regev - Executive Vice President, Genentech Research and Early Development
Wafaa Mamilli - Executive Vice President, Chief Digital Technology Officer
Dara Pincas - Head of Global Legal Pharma, General Counsel, Corporate Secretary
Tricia Stewart - Chief People Officer
Tongtong Wang - Global Head, Pharma Technical Research & Development
Fritz Bittenbender - Senior Vice President, Head of Genentech Public Affairs & Access
Katie Peng - Senior Vice President, Sales & Marketing
Scientific Founders:Herbert W. Boyer, Robert A. Swanson
LINKS
Website:gene.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Genentech. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.